Department of Surgery, University of California San Francisco, San Francisco, California; Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Department of Surgery, University of California San Francisco, San Francisco, California.
Surg Obes Relat Dis. 2020 Aug;16(8):1124-1132. doi: 10.1016/j.soard.2020.04.026. Epub 2020 May 4.
Bariatric surgery is the most effective long-term treatment for obesity. Opioid-sparing anesthesia and multimodal analgesia such as lidocaine infusion have been recommended in these patients to reduce opioid-related complications. However, evidence supporting its use for bariatric surgery population is limited.
To investigate whether intraoperative lidocaine infusion is associated with decreasing opioid consumption in laparoscopic bariatric surgery.
A university hospital, California, USA.
In this retrospective cohort study, outcomes among consecutive obese patients undergoing laparoscopic bariatric surgery between January 2016 to December 2018 were evaluated to determine the impact of adjunctive intraoperative lidocaine infusion on 24-hour postoperative opioid consumption. Secondary outcomes, including opioid consumption during hospitalization, length of stay, and postoperative complications were determined. Post hoc analyses were performed exploring possible dose effects and drug-drug interactions. Univariable and multivariable analyses were performed to identify factors associated with opioid consumption.
Among 345 patients, 54 (15.7%) received intraoperative lidocaine infusion (L+) whereas 291 (84.3%) did not receive intraoperative lidocaine infusion (L-). Both L+ and L- groups shared similar demographic characteristics. The 24-hour postoperative opioid consumption was 17.6% lower in L+ (95% confidence interval -28.4 to -5.2, P = .007), but nonsignificantly lower in the multivariate model (12.8%, 95% confidence interval -24.4 to .5, P = .06). Opioid consumption during hospitalization, length of stay, and other clinically significant outcomes did not differ. However, subgroup analysis restricted to opioid-naïve patients indicated significantly reduced opioid consumption in the L+ group. Post hoc analysis suggested interaction between lidocaine and ketamine in decreasing 24-hour postoperative opioid consumption.
Intraoperative lidocaine infusion was not significantly associated with decreasing 24-hour postoperative opioid consumption in obese patients undergoing laparoscopic bariatric surgery.
减重手术是治疗肥胖症最有效的长期治疗方法。在这些患者中,建议使用阿片类药物节约型麻醉和多模式镇痛,如利多卡因输注,以减少与阿片类药物相关的并发症。然而,支持其用于减重手术人群的证据有限。
研究腹腔镜减重手术中术中利多卡因输注是否与减少阿片类药物消耗有关。
美国加利福尼亚州的一所大学医院。
在这项回顾性队列研究中,评估了 2016 年 1 月至 2018 年 12 月期间连续接受腹腔镜减重手术的肥胖患者的结局,以确定辅助术中利多卡因输注对术后 24 小时阿片类药物消耗的影响。确定了其他次要结局,包括住院期间的阿片类药物消耗、住院时间和术后并发症。进行了事后分析,以探索可能的剂量效应和药物相互作用。进行了单变量和多变量分析,以确定与阿片类药物消耗相关的因素。
在 345 名患者中,54 名(15.7%)接受了术中利多卡因输注(L+),而 291 名(84.3%)未接受术中利多卡因输注(L-)。L+和 L-组具有相似的人口统计学特征。L+组术后 24 小时阿片类药物消耗降低 17.6%(95%置信区间-28.4 至-5.2,P=0.007),但在多变量模型中差异无统计学意义(12.8%,95%置信区间-24.4 至 0.5,P=0.06)。住院期间的阿片类药物消耗、住院时间和其他有临床意义的结局没有差异。然而,在阿片类药物-naive 患者的亚组分析中,L+组的阿片类药物消耗明显减少。事后分析表明,利多卡因和氯胺酮之间存在相互作用,可减少术后 24 小时阿片类药物消耗。
腹腔镜减重手术中术中利多卡因输注与肥胖患者术后 24 小时阿片类药物消耗的减少无显著相关性。